Clear All
11465 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
24338-0154-01 24338-0154 Nilotinib DANZITEN 71.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 30, 2024 In Use
24338-0155-01 24338-0155 Nilotinib DANZITEN 95.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 30, 2024 In Use
57894-0503-01 57894-0503 Daratumumab and hyaluronidase-fihj (human recombinant) Darzalex Faspro 1800.0 mg/15mL, 4.9 mg/15mL, 18.4 mg/15mL, 30000.0 U/15mL, 13.5 mg/15mL, 6.0 mg/15mL, 735.1 mg/15mL Immunotherapy Monoclonal Antibody CD38 Subcutaneous May 1, 2020 In Use
57894-0505-20 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct 15, 2021 In Use
57894-0505-05 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct 15, 2021 In Use
57894-0502-20 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov 16, 2015 Nov 30, 2026 In Use
57894-0502-05 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov 16, 2015 Oct 31, 2026 In Use
70377-0083-11 70377-0083 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
70771-1903-06 70771-1903 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
70771-1902-06 70771-1902 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
60505-3630-06 60505-3630 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
70710-1743-06 70710-1743 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
66993-0238-30 66993-0238 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
66993-0234-60 66993-0234 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
43598-0599-60 43598-0599 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
66993-0235-60 66993-0235 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
70771-1905-03 70771-1905 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
70377-0087-11 70377-0087 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
70771-1901-06 70771-1901 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
60505-3816-03 60505-3816 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
70710-1741-06 70710-1741 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
70710-1746-03 70710-1746 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
43598-0600-60 43598-0600 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
66993-0233-60 66993-0233 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
60505-3817-03 60505-3817 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use

Found 11465 results — Export these results